Topic: Sanofi-Aventis SA
LONDON/PARIS (Reuters) - Three of Europe's biggest drugmakers -- AstraZeneca , Novartis and Sanofi -- reported product setbacks on Tuesday, underlining the difficulties of developing new medicines to make up for those going off patent.With the weakest pipeline of its European peers, ...
LONDON (Reuters) - Roche is set to kick off the Big Pharma reporting season with a fall in sales on Thursday as a strong Swiss franc, weak demand for top-selling cancer drug Avastin and lack of Tamiflu revenue take their toll.The absence ...
PARIS (Reuters) - French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme, allowing it to begin merging the U.S. biotech firm into its business and add rare diseases to its growth areas.Sanofi said 84.6 percent of Genzyme's common stock had ...
PARIS/LONDON (Reuters) - Regulatory pressure prompted Sanofi-Aventis and Merck & Co to abandon plans for a joint animal health powerhouse with $5 billion in sales.The move sets back the French and U.S. drugmakers' plans to achieve economies of scale in the consolidating ...
NEW YORK (Reuters) - Genzyme Corp Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final -- and stands to earn considerably more should Genzyme's multiple sclerosis ...
WASHINGTON (Reuters) - The Food and Drug Administration warned Sanofi-Aventis SA's U.S. unit for failing to tell the agency about reports of possible serious side effects in a timely manner.In a January 28 letter made public on Tuesday, the FDA said an ...
PARIS (Reuters) - French drugmaker Sanofi-Aventis has agreed to buy Genzyme Corp for $20.1 billion in cash, plus payments tied to the success of the company's drugs, the companies said on Wednesday.Sanofi will pay $74 a share in cash and a contingent ...
BOSTON (Reuters) - Sanofi-Aventis SA has agreed in principle to acquire Genzyme Corp for $19.2 billion in cash plus future payments based on the performance of an experimental Genzyme drug, according to two sources with knowledge of the talks.Under the agreement, Genzyme ...
PHILADELPHIA (Reuters) - Sanofi-Aventis has completed a review of the financial books and operations of takeover target Genzyme Corp , but the two sides continue to discuss a final price for a potential deal, according to The Wall Street Journal.Sanofi did not ...
PARIS (Reuters) - French drugmaker Sanofi-Aventis reported progress in talks to buy U.S. biotech firm as it predicted 5-10 percent lower earnings this year."As we announced about 10 days ago, we have signed a confidentiality agreement with Genzyme," Chief Executive Chris Viehbacher ...
From Around the Web
Video Gallery
-
Mergers & Acquisitions: Sanofi-Aventis SA Bids $18...
"Sanofi-Aventis (NYSE:SNY) making a hostile $18.5 billion bid ...2010-10-04 -
Sanofi-Aventis Seeking Suitor For US Dermatology ...
Sanofi-Aventis SA (NYSE:SNY), France's largest drug maker, is ...2011-04-14 -
SRS (SA) 2009 Sanofi-Aventis Prize Winner
Dr David Muchuweti Abdominal Surgical Site Infection: Risk factors and ...2010-02-04
